Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 1

Bioavailability Section

Comparative pharmacokinetics of new curcumin preparations and evidence for increased bioavailability in healthy adult participants 

Akiko Hirose, Yoshitaka Kuwabara, Yoko Kanai, Chieko Kato, Yuji Makino, Fukumoto Yoshi, and Kazumoto Sasaki

###ENGLISH_ABSTRACT_LINK### ###FREE_ENGLISH_ARTICLE_DOWNLIAD_LINK###

Volume 60 (2022) p. 530 - 538

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 60 – No. 12/2022 (530-538)

Comparative pharmacokinetics of new curcumin preparations and evidence for increased bioavailability in healthy adult participants 

Akiko Hirose¹, Yoshitaka Kuwabara¹, Yoko Kanai², Chieko Kato³, Yuji Makino³, Fukumoto Yoshi⁴, and Kazumoto Sasaki⁴

¹Department of R&D, Theravalues Corp., ²CRO Business Div., Apo Plus Station Co. Ltd., ³Institute for Pharmaceutical Research, Musashino University, Tokyo, and ⁴Sasaki Memorial Hospital, Tokorozawa, Saitama, Japan
Objective: Theracurmin, which contains the curcumin composition, CR-033P, has been demonstrated to be highly bioavailable. To compare the pharmacokinetics of the three compositions, CR-033P, CR-043P using modified starch as an alternative to the dispersant gum ghatti used in the CR-033P, and TS-P1 containing the newly developed amorphous curcumin, a randomized double-blind crossover study (3-way, 3-period) was conducted.
Materials and methods: A single dose of the curcumin capsules (TS-P1 45 mg, CR-033P 90 mg, and CR-043P 90 mg) was administered to healthy adult participants. Blood sampling was performed 24 hours after capsule administration, and the plasma concentration of total curcumin was determined using high-performance liquid chromatography coupled with tandem mass spectrometry.
Results: TS-P1 and CR-043P tended to have a slightly lower area under the concentration time curve (AUC) _0–24h than CR-033P, while TS-P1 displayed bioequivalence to CR-043P. Further, TS-P1 displayed bioequivalence to CR-033P in terms of AUC_0–12h, while that of CR-043P tended to be lower than that of CR-033P. TS-P1 had a higher AUC_0–12h than CR-043P. A statistically significant difference (p < 0.001) was found between the preparations in terms of C_max. TS-P1 tended to have a higher C_max than CR-033P, CR-043P tended to have a slightly lower C_max than CR-033P, and TS-P1 tended to have a higher C_max than CR-043P.
Conclusion: The newly developed TS-P1 composition seemed to display similar curcumin systemic exposure except for a higher plasma concentration than the CR-033P composition. Further, only a few significant differences were found between CR-043P and CR-033P.Correspondence to:
Akiko Hirose, Research fellow
Department of R&D, Theravalues Corp.
1F Kioicho Bldg. 3-12 Kioicho chiyoda-ku
Tokyo 102-0094, Japan
Email: [email protected]

Warenkorb Übersicht

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail